AstraZeneca top loser on FTSE 100 after heart disease drug fails late-stage trial
09/07/2026 08:26
BUZZ-AstraZeneca top loser on FTSE 100 after heart disease drug fails late-stage trial ** Shares of AstraZeneca AZN.L slump as much as 9.6% to 12,874p; on track for their worst day since 2017
** AZN is top loser on FTSE 100 .FTSE index, which is down 0.4%
** Co says its nerve disease drug Wainua, made in partnership with Ionis IONS.O, failed to meet main goal of reducing cardiovascular deaths & recurring heart problems in a late-stage trial
** AZN down 6% YTD
(Reporting by Nithyashree R B in Bengaluru)
Recent news on Ionis Pharmaceuticals
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Focus: AI companies run virtual drug trials, aim to improve success of human studies
Brief: Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile
Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study